Prof. Dr. Katharina Blankart, MBR

Prof. Dr. Katharina Blankart, MBR

Business Economist, Health & Innovation

Sitemap

A list of all the posts and pages found on the site. For you robots out there is an XML version available for digesting as well.

Pages

Posts

Future Blog Post

less than 1 minute read

Published:

This post will show up by default. To disable scheduling of future posts, edit config.yml and set future: false.

Blog Post number 4

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 3

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 2

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

Blog Post number 1

less than 1 minute read

Published:

This is a sample blog post. Lorem ipsum I can’t remember the rest of lorem ipsum and don’t have an internet connection right now. Testing testing testing this blog post. Blog posts are cool.

publications

Publications

Published in , 1900

Peer-reviewed journal articles

Blankart KE, Stargardt T. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics. 2020;29(S1):63–82.

Blankart KE, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Manag Sci. 2020 Aug 8;23:605–18.

Blankart KE, Arndt F. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. International Journal of Environmental Research and Public Health. 2020 Jan;17(11):4113.

Winter V, Thomsen MK, Schreyögg J, Blankart K, Duminy L, Schoenenberger L, et al. Improving Service Provision - The Health Care Services’ Perspective. SMR. 2019;3(4):163–83.

Guhl D, Blankart KE, Stargardt T. Service quality and perceived customer value in community pharmacies. Health Services Management Research. 2019 Feb 1;32(1):36–48.

Fischer KE, Koch T, Kostev K, Stargardt T. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2018 Mar 1;19(2):213–22.

Hostenkamp G, Fischer KE, Borch-Johnsen K. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy. 2016;120(12):1404–11.

Guhl D, Stargardt T, Schneider U, Fischer KE. Dispensing behaviour of pharmacies in prescription drug markets. Health Policy. 2016 Feb;120(2):190–7.

Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016 Nov 1;17(8):1027–40.

Fischer KE, Heisser T, Stargardt T. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy. 2016 Oct;120(10):1115–22.

Fischer KE, Stargardt T. Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. Med Decis Making. 2014 Nov 1;34(8):1030–47.

Fischer KE, Rogowski WH. Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. International Journal of Environmental Research and Public Health. 2014 May 19;11(5):5403–30.

Fischer KE, Leidl R. Analysing coverage decision-making: opening Pandora’s box? Eur J Health Econ. 2014;15(9):889–906.

Fischer KE, Stollenwerk B, Rogowski WH. Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.

Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013 Oct;112(3):187–96.

Fischer KE. Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. BMC Medical Informatics and Decision Making. 2012 Aug 2;12(1):83.

Fischer KE. A systematic review of coverage decision-making on health technologies—Evidence from the real world. Health Policy. 2012;107(2–3):218–30.

Fischer KE, Leidl R, Rogowski WH. A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. Health Policy. 2011 Aug;101(3):290–9.

Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. International Journal of Technology Assessment in Health Care. 2011;27(04):313–21.

Book chapters

Blankart K. Heilung um jeden Preis? - Die 20.000€ Pille oder die Herausforderung der Preissetzungsstrategie im Gesundheitswesen. In: Ritz A, Sager F, Lienhard A, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)

Blankart K. Der strategische Kampf: Wettbewerbsfähigkeit durch die europäische Waren- und Dienstleistungsfreiheit. In: Ritz A, Sager F, Lienhard A, Blankart CRB, editors. Fälle zu Public Management und Verwaltungswissenschaft. (forthcoming)

Articles in German

Kurte MS, Blankart K. Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. Gesundh ökon Qual manag. 2019 May 7;24(06):277–91.

Fischer K. Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013;19(3):67–81.

resources

talks

teaching

workinprogress

workshops